Abstract: A gas turbine system includes a compressor section, a turbine section, a combustor section. The combustor section is in fluid communication with a fuel supply via a fuel supply line. The water circuit includes a first water line extending between a first feed water supply line and a return water line. The gas turbine system further includes an extraction-air line that extends between an inlet port on the compressor section and an outlet port on the turbine section. A first heat exchanger thermally couples the first water line to the extraction-air line for transferring heat from a flow of extraction-air within the extraction-air line to a flow of water within the water circuit. A second heat exchanger thermally couples the first water line to the fuel supply line for transferring heat from the flow of water within the water circuit to a flow of fuel within the fuel supply line.

Abstract: A gas turbine system includes a compressor section, a turbine section, a combustor section. The combustor section is in fluid communication with a fuel supply via a fuel supply line. The water circuit includes a first water line extending between a first feed water supply line and a return water line. The gas turbine system further includes an extraction-air line that extends between an inlet port on the compressor section and an outlet port on the turbine section. A first heat exchanger thermally couples the first water line to the extraction-air line for transferring heat from a flow of extraction-air within the extraction-air line to a flow of water within the water circuit. A second heat exchanger thermally couples the first water line to the fuel supply line for transferring heat from the flow of water within the water circuit to a flow of fuel within the fuel supply line.

Abstract: The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R1, R2, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.

Abstract: A combustion turbine engine that includes: a compressor; a combustor that receives fuel from a fuel line; a turbine; a heat exchange portion comprising a portion of the fuel line in heat transfer relationship with a heat source for heating the fuel; a rapid heating value meter disposed to test the heating value of the fuel that is configured to provide heating value test results within approximately 1 minute; a cold leg bypass comprising a fuel line that bypasses the heat exchange portion, the cold leg bypass being connected to the fuel line at an upstream fork and at a fuel mixing junction; and valves for controlling the fuel being directed through the heat exchange portion and the fuel being direct through the cold leg bypass; wherein the length of fuel line between the fuel mixing junction and the combustor is less than 20 meters.

Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.

Abstract: A combustion turbine engine that includes: a compressor; a combustor that receives fuel from a fuel line; a turbine; a heat exchange portion comprising a portion of the fuel line in heat transfer relationship with a heat source for heating the fuel; a rapid heating value meter disposed to test the heating value of the fuel that is configured to provide heating value test results within approximately 1 minute; a cold leg bypass comprising a fuel line that bypasses the heat exchange portion, the cold leg bypass being connected to the fuel line at an upstream fork and at a fuel mixing junction; and valves for controlling the fuel being directed through the heat exchange portion and the fuel being direct through the cold leg bypass; wherein the length of fuel line between the fuel mixing junction and the combustor is less than 20 meters.

Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.

Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The invention relates to the use of hydantoin compounds useful for treating or preventing autoimmune disorders. The present invention also provides compositions and uses thereof.

Abstract: The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The invention relates to the use of hydantoin compounds useful for treating or preventing autoimmune disorders. The present invention also provides compositions and uses thereof.

Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.

Abstract: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

Abstract: The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.